CVS Health’s SWOT analysis: stock faces margin recovery test

CVS Health Corporation (NYSE:CVS) stands at a critical juncture as the healthcare giant pursues an ambitious multi-year transformation aimed at achieving substantial earnings growth through 2028. The stock currently trades at $102.08, near its 52-week high of $106.15, reflecting strong investor confidence with a remarkable 59% return over the past year. According to InvestingPro analysis, CVS remains undervalued relative to its Fair Value, placing it among opportunities on the most undervalued stocks list. The company’s integrated model spanning pharmacy benefit management, retail pharmacy operations, and health insurance through its Aetna division positions it uniquely within the evolving healthcare landscape, though execution challenges and regulatory uncertainties continue to test investor confidence.

Strategic vision targets aggressive earnings growth

CVS Health has outlined a strategic roadmap targeting earnings per share of $9.50 by fiscal year 2028, representing mid-teens percentage growth annually from current levels. This ambitious target relies heavily on margin recovery across the company’s Health Care Benefits segment, which includes the Aetna insurance operations, and its Health Services Segment encompassing pharmacy benefit management and Oak Street Health operations.

The company’s fiscal year 2026 earnings per share estimate stands at $7.37 according to recent analyst projections, slightly below the consensus expectation of $7.42. InvestingPro data shows an EPS forecast of $7.46 for fiscal 2026, while the stock currently trades at a P/E ratio of 44.48, reflecting market expectations for the company’s transformation. This positions the company to deliver approximately 29 percent growth over the subsequent two years to reach the 2028 target, assuming successful execution of margin improvement initiatives.

For fiscal year 2025, earnings per share estimates ranged from $6.66 to $6.70, establishing the baseline from which CVS Health must accelerate growth. The progression from fiscal year 2025 through fiscal year 2026 and beyond represents a critical test of management’s ability to deliver on operational improvements while navigating a complex regulatory environment.

Health Care Benefits segment shows mixed signals

The Health Care Benefits segment, which houses CVS Health’s Aetna insurance operations and Medicare Advantage products, presents both opportunity and challenge for the company’s growth trajectory. Analysts anticipate the segment could perform in line with or potentially exceed expectations, with utilization trends potentially favoring better-than-anticipated results.

The medical loss ratio, a key metric measuring the proportion of premium revenue spent on medical claims, is projected at 90.9 percent for 2026, slightly above the consensus estimate of 90.3 percent. This 60-basis-point differential suggests either more conservative assumptions about medical cost management or expectations for higher utilization than the broader analyst community anticipates.

Medicare Advantage represents a significant growth opportunity for CVS Health, with the company positioned to benefit from favorable regulatory catalysts and margin improvements in this market. Supporting this growth trajectory, InvestingPro Tips highlight that CVS has maintained dividend payments for 56 consecutive years and net income is expected to grow this year, demonstrating financial resilience. Investors can access 10 additional ProTips on the platform for deeper insights into CVS’s investment potential. The Medicare Advantage business offers potential for year-over-year margin expansion, which could materially contribute to overall earnings per share growth.

Medicaid operations face headwinds, with year-to-date enrollment declining an estimated 1.8 percent through May 2026. This enrollment pressure reflects broader industry trends as states complete Medicaid redetermination processes following pandemic-era continuous coverage provisions. The decline aligns with patterns observed across managed care organizations operating in the Medicaid space.

Pharmacy benefit management stability provides foundation

The pharmacy benefit management business, a core component of CVS Health’s integrated model, appears positioned for stable performance following a period of industry disruption and competitive pressures. Analysts view the stable outlook for PBM operations as a positive development, removing a significant source of uncertainty that had previously weighed on investor sentiment.

The shift to a stable outlook for the Pharmacy Care Writing operations represents an important inflection point. This segment had faced questions about competitive dynamics and pricing pressures, making the stabilization a key element supporting the company’s broader growth targets.

PBM operations generate revenue through drug formulary management, mail-order pharmacy services, and specialty pharmacy operations. The business model benefits from CVS Health’s vertical integration with retail pharmacy locations and insurance operations, creating potential synergies unavailable to standalone PBM competitors.

Care delivery expansion supports margin improvement

CVS Health’s Care Delivery operations, including the Oak Street Health primary care clinics acquired in recent years, represent a strategic investment in value-based care models. This segment is expected to contribute to margin improvement as the company scales operations and realizes efficiencies from integration with existing health plan and pharmacy assets.

The Care Delivery segment aligns with broader healthcare industry trends toward value-based reimbursement models that reward providers for managing total cost of care rather than fee-for-service volume. CVS Health’s ability to connect primary care delivery with pharmacy services and health insurance creates potential advantages in managing patient populations.

Margin expansion in Care Delivery depends on achieving sufficient scale and successfully managing the transition from growth investment phase to profitability. The timeline for this segment to become a meaningful earnings contributor remains a key question for investors evaluating the company’s long-term prospects.

Regulatory environment creates uncertainty

Recent legal decisions affecting Medicare Advantage Star ratings calculations have introduced uncertainty into CVS Health’s outlook. The Star ratings system determines quality bonus payments and influences beneficiary enrollment decisions, making it a material factor in Medicare Advantage profitability.

Potential recalculations of Star ratings following legal challenges could affect revenue and profitability in the Health Care Benefits segment. The magnitude and timing of any adjustments remain unclear, creating an overhang on near-term earnings visibility.

The regulatory environment for pharmacy benefit managers continues to evolve, with federal and state policymakers scrutinizing PBM business practices and reimbursement models. Changes to PBM regulations could affect revenue recognition, profit margins, or competitive dynamics in ways that impact CVS Health’s financial performance.

Bear Case

Can CVS overcome persistent Medicaid enrollment declines?

The 1.8 percent year-to-date decline in Medicaid enrollment through May 2026 represents a meaningful headwind for CVS Health’s Health Care Benefits segment. Medicaid members typically generate lower per-member revenue than Medicare Advantage or commercial insurance enrollees, but the volume of covered lives contributes to overall scale and risk pool diversification.

Continued Medicaid enrollment pressure could persist as states complete redetermination processes and implement stricter eligibility verification procedures. If enrollment declines accelerate or extend beyond current expectations, CVS Health may face challenges maintaining the member base necessary to support fixed costs in its insurance operations.

The company’s ability to offset Medicaid losses through Medicare Advantage growth becomes critical in this scenario. If Medicare Advantage enrollment fails to grow sufficiently or faces its own regulatory headwinds, the net impact on Health Care Benefits segment performance could fall short of the margin improvement targets embedded in the company’s 2028 earnings per share goal.

Will regulatory uncertainty derail Medicare Advantage margin expansion?

The uncertainty surrounding Medicare Advantage Star ratings recalculations poses a direct threat to CVS Health’s margin improvement thesis. Star ratings determine quality bonus payments that can represent several percentage points of revenue for high-performing plans. A downward revision to Star ratings would reduce bonus payments and potentially affect member retention as beneficiaries compare plan quality scores during annual enrollment periods.

The medical loss ratio projection of 90.9 percent already sits above consensus expectations, suggesting limited margin cushion if medical costs trend higher than anticipated or if revenue faces pressure from regulatory changes. Medicare Advantage plans operate in a highly regulated environment where reimbursement rates are set annually by the Centers for Medicare and Medicaid Services, limiting the company’s ability to offset cost pressures through price increases.

If regulatory challenges compound with higher-than-expected medical utilization, CVS Health could struggle to achieve the margin expansion necessary to reach its ambitious earnings per share targets. The company’s valuation and investor sentiment remain sensitive to execution in the Health Care Benefits segment, making regulatory setbacks particularly consequential for stock performance.

Bull Case

Can margin improvements drive CVS to its ambitious earnings targets?

CVS Health’s integrated business model creates multiple pathways for margin expansion that could support achievement of the $9.50 earnings per share target by 2028. The combination of pharmacy benefit management, retail pharmacy, insurance operations, and primary care delivery offers opportunities for operational synergies unavailable to less diversified competitors.

Margin recovery in the Aetna Health Care Benefits segment represents the most significant earnings driver in the company’s strategic plan. As medical cost trends stabilize and the company refines its underwriting and network management capabilities, margins could expand meaningfully from current levels. Even modest improvement in the medical loss ratio translates to substantial earnings per share impact given the scale of the insurance operations.

The Care Delivery segment, while currently in investment mode, offers long-term margin expansion potential as value-based care models mature and the company achieves scale efficiencies. Integration of Oak Street Health primary care clinics with Aetna insurance products creates opportunities to manage total cost of care more effectively than traditional fee-for-service models.

Stability in the pharmacy benefit management business removes a source of earnings pressure that had weighed on results in prior periods. With competitive dynamics stabilizing and the company maintaining its position serving health plans and employers, PBM operations can contribute consistent cash flow to fund investments in higher-growth segments.

Will Medicare Advantage expansion offset other segment pressures?

Medicare Advantage represents one of the fastest-growing segments of the U.S. healthcare market, with penetration of the eligible Medicare population continuing to increase as beneficiaries shift from traditional fee-for-service Medicare to managed care plans. CVS Health’s strong positioning in this market creates opportunities for enrollment growth and margin expansion.

The company’s vertical integration offers competitive advantages in Medicare Advantage that could drive market share gains. The ability to direct members to CVS retail pharmacy locations, manage pharmacy benefits through the integrated PBM, and coordinate care through Oak Street Health clinics creates a differentiated value proposition for beneficiaries and a more manageable cost structure for the company.

Regulatory catalysts could provide tailwinds for Medicare Advantage profitability. If Star ratings recalculations resolve favorably or if reimbursement rate updates from the Centers for Medicare and Medicaid Services exceed expectations, CVS Health could see upside to current margin projections. The company’s scale and operational capabilities position it to benefit disproportionately from favorable regulatory developments.

Year-over-year margin improvement in Medicare Advantage, even if modest, compounds over the multi-year period through 2028 to create substantial earnings per share contribution. If the company successfully executes on margin expansion while maintaining or growing enrollment, the Medicare Advantage business alone could drive significant progress toward the $9.50 earnings per share target.

SWOT Analysis

Strengths

• Integrated business model spanning pharmacy benefit management, retail pharmacy, insurance, and primary care delivery
• Strong market position in Medicare Advantage with opportunities for margin expansion
• Diversified revenue streams across multiple healthcare sectors reduce dependence on any single business line
• Scale advantages in pharmacy operations and health insurance provide competitive moat
• Clear strategic vision with specific financial targets through fiscal year 2028

Weaknesses

• Medical loss ratio projections above consensus expectations suggest margin pressure
• Medicaid enrollment declines create headwinds for Health Care Benefits segment growth
• Execution risk associated with ambitious earnings per share targets
• Integration complexity across multiple business segments requires sustained management focus
• Limited near-term margin cushion if medical costs or utilization trends unfavorably

Opportunities

• Margin recovery in Aetna and Care Delivery segments could drive substantial earnings growth
• Medicare Advantage market growth provides favorable industry tailwinds
• Value-based care models align with company’s integrated capabilities
• Pharmacy benefit management stability removes source of prior earnings uncertainty
• Potential for favorable regulatory developments in Medicare Advantage reimbursement

Threats

• Regulatory uncertainty surrounding Medicare Advantage Star ratings recalculations
• Continued Medicaid enrollment pressures as states complete redetermination processes
• Evolving pharmacy benefit manager regulations could affect business model or margins
• Medical cost inflation or utilization increases could prevent margin expansion
• Competitive pressures in Medicare Advantage market from other national and regional health plans

Analyst Targets

• Morgan Stanley: June 30, 2026 - Overweight rating
• Cantor Fitzgerald: January 7, 2026 - Overweight rating, $95.00 price target
• Barclays Capital Inc.: December 10, 2025 - Overweight rating, $93.00 price target

This analysis is based on information available from December 2025 through June 2026. For comprehensive analysis, CVS is one of 1,400+ US equities covered by InvestingPro’s Pro Research Reports, which transform complex Wall Street data into clear, actionable intelligence through intuitive visuals and expert analysis.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on CVS. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore CVS’s full potential at InvestingPro.

Should you invest in CVS right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if CVS is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate CVS further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if CVS appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.